A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children
Study Details
Study Description
Brief Summary
The study is being conducted to evaluate the efficacy, safety and the population pharmacokinetic characteristics of dexmedetomidine hydrochloride nasal spray for preoperative sedation in children
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: High weight group High weight group |
Drug: Dexmedetomidine hydrochloride nasal spray
In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.
In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray.
Drug: Dexmedetomidine hydrochloride nasal spray blank preparation.
In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
Other Names:
|
Experimental: Low weight group Low weight group |
Drug: Dexmedetomidine hydrochloride nasal spray
In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.
In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray.
Drug: Dexmedetomidine hydrochloride nasal spray blank preparation.
In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- PK Cmax [0 to 1 hour after administration]
Maximum blood concentration (Cmax)
Secondary Outcome Measures
- Proportion of subjects who parent-child separation successful [0 minute to 45 minutes after administration: every 15 minutes after administration]
The FUNK scale is a scale of 1 to 4 for sedation, anxiety, and separation from parents. Separation success defined as a scale of 3 or 4 per item.
- Proportion of subjects who the Ramsay score is satisfactory at least once [0 minute to 45 minutes after administration: every 5 minutes after administration]
Sedation level using the Ramsay scale. Ramsay Satisfaction defined as a scale of 2, 3, or 4;
- Proportion of subjects who the UMSS Scale is satisfactory at least once [0 minute to 45 minutes after administration: every 5 minutes after administration]
Sedation level using the University of Michigan Sedation Scale. UMSS satisfaction defined as a scale of 3, 4, 5, or 6;
- Total consumption of propofol(mg) during general anesthesia [From the beginning of anesthesia to the end of surgical operation up to 4 hours]
Total consumption of propofol(mg) during general anesthesia
- Total consumption of opioid analgesic(μg) during general anesthesia [From the beginning of anesthesia to the end of surgical operation up to 4 hours]
Total consumption of opioid analgesic(μg) during general anesthesia
- Time of anesthesia awakening [Up to 4 hours after the end of surgical operation]
Time of anesthesia awakening
- Proportion of subjects with postoperative agitation [Up to 4 hours after the end of surgical operation]
Proportion of subjects with postoperative agitation
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Able and willing to provide a written informed consent
-
Male or female
-
Subjects requiring elective general anesthesia surgery
-
Conform to the ASA Physical Status Classification
-
Meet the weight standard
Exclusion Criteria:
-
Not suitable for nasal spray
-
Pediatric populations requiring special care or court/social welfare supervision
-
Subjects who had been under general anesthesia were randomized
-
Subjects with mental disorders and cognitive impairment;Subject with a history of epilepsy
-
Subjects with previous abnormal behavior after medication
-
Subjects with cardiovascular disease
-
Clinically significant abnormal clinical laboratory test value
-
Subjects whose hemoglobin is below the lower limit of normal
-
Subjects who have either an adrenergic receptor agonist or an antagonist were randomized
-
Participated in clinical trials of other drugs before screening (accepted experimental drugs)
-
A history or possibility of difficult airway
-
History of hypersensitivity to drug ingredients or components
-
Other circumstances that the investigator judged inappropriate for participation in this clinical trial
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Beijing children's hospital, capital medical university | Beijing | Beijing | China | 100045 |
Sponsors and Collaborators
- Jiangsu HengRui Medicine Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HR0171401-102